argenx NV ADR (ARGX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
argenx NV ADR stock (ARGX) is currently trading at $697.05. argenx NV ADR PE ratio is 34.60. argenx NV ADR PS ratio (Price-to-Sales) is 9.93. Analyst consensus price target for ARGX is $1021.20. WallStSmart rates ARGX as Hold.
- ARGX PE ratio analysis and historical PE chart
- ARGX PS ratio (Price-to-Sales) history and trend
- ARGX intrinsic value — DCF, Graham Number, EPV models
- ARGX stock price prediction 2025 2026 2027 2028 2029 2030
- ARGX fair value vs current price
- ARGX insider transactions and insider buying
- Is ARGX undervalued or overvalued?
- argenx NV ADR financial analysis — revenue, earnings, cash flow
- ARGX Piotroski F-Score and Altman Z-Score
- ARGX analyst price target and Smart Rating
argenx NV ADR
📊 No data available
Try selecting a different time range
ARGX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · argenx NV ADR (ARGX)
ARGX trades 527% above its Graham fair value of $133.14, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
argenx NV ADR (ARGX) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, return on equity. Concerns around price/sales and price/book. Fundamentals are solid but monitor weak areas for improvement.
argenx NV ADR (ARGX) Key Strengths (6)
Growing significantly faster than its price suggests
Revenue surging 73.00% year-over-year
Keeps $31 of every $100 in revenue as net profit
Large-cap company with substantial market presence
Every $100 of equity generates $20 in profit
Strong operational efficiency: $27 kept per $100 revenue
Supporting Valuation Data
argenx NV ADR (ARGX) Areas to Watch (4)
Earnings declining -31.90%, profits shrinking
Very expensive at 9.9x annual revenue
Very expensive at 5.7x book value
Moderate institutional interest at 48.99%
Supporting Valuation Data
argenx NV ADR (ARGX) Detailed Analysis Report
Overall Assessment
This company scores 63/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 6 register as strengths (avg 9.3/10) while 4 fall into concern territory (avg 2.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Revenue Growth, Profit Margin. Valuation metrics including PEG Ratio (0.83) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 20.20%, Operating Margin at 27.40%, Profit Margin at 30.50%. Growth metrics are encouraging with Revenue Growth at 73.00%.
The Bear Case
The primary concerns are EPS Growth, Price/Sales, Price/Book. Some valuation metrics including Price/Sales (9.93), Price/Book (5.74) suggest expensive pricing. Growth concerns include EPS Growth at -31.90%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 20.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 73.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Revenue Growth) and negatives (EPS Growth, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARGX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARGX's Price-to-Sales ratio of 9.93x trades at a deep discount to its historical average of 44.41x (4th percentile). The current valuation is 94% below its historical high of 172.19x set in Feb 2021, and 5% above its historical low of 9.42x in Aug 2017. Over the past 12 months, the PS ratio has compressed from ~13.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for argenx NV ADR (ARGX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
argenx NV ADR is a strong growth company balancing expansion with improving profitability. Revenue reached 4.2B with 73% growth year-over-year. Profit margins are strong at 30.5%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 73% YoY, reaching 4.2B. This pace significantly outperforms most BIOTECHNOLOGY peers.
ROE of 20.2% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can argenx NV ADR maintain 73%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact argenx NV ADR.
Bottom Line
argenx NV ADR offers an attractive blend of growth (73% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:09:51 AM
About argenx NV ADR(ARGX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.